Document Detail

Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction.
MedLine Citation:
PMID:  2973215     Owner:  NLM     Status:  MEDLINE    
Left ventricular (LV) hypertrophy is known to be an independent risk factor for cardiac death, but its significance in non-Q-wave acute myocardial infarction (AMI) has not been assessed previously. In a randomized diltiazem-placebo-controlled therapeutic trial of non-Q-wave AMI confirmed by creatine kinase-MB (CK-MB), 126 of 544 patients (23%) exhibited LV hypertrophy using standard voltage criteria. Compared to patients without LV hypertrophy, patients with LV hypertrophy were significantly older (65 vs 60 years, p less than 0.0001) and had smaller peak adjusted CK levels (490 +/- 376 vs 666 +/- 726 IU/liter, p less than 0.001) than patients without LV hypertrophy. Patients with and without LV hypertrophy did not differ significantly in acute mortality during hospitalization, progression to Q waves, reinfarction by CK-MB criteria or angina associated with transient electrocardiographic changes. Compared with patients without LV hypertrophy, those patients with non-Q-wave AMI and LV hypertrophy had a 2-fold higher incidence of reinfarction (24 vs 12%, p less than 0.005) and death (19 vs 9%, p = 0.044) during the first year of follow-up. Multivariate regression analysis revealed that the relative risk of death and reinfarction during the initial year after AMI was increased by a factor of 1.7 and 2.1 among patients with LV hypertrophy, respectively. It was therefore concluded that, although patients with LV hypertrophy and non-Q-wave AMI have smaller enzymatic infarcts and the same short-term prognosis as do patients without LV hypertrophy, their reinfarction and mortality rates are significantly increased during the first year of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
W E Boden; R E Kleiger; K B Schechtman; R J Capone; D J Schwartz; R S Gibson
Related Documents :
19573735 - Fundamental differences in electrophysiologic and electroanatomic substrate between isc...
19356515 - Cardiac chamber volumes, function, and mass as determined by 64-multidetector row compu...
12695295 - Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor ...
20962345 - Long-term prognostic value of left ventricular dyssynchrony assessment by phase analysi...
8077555 - Attenuation of coronary flow reserve and myocardial function after temporary subtotal c...
24903195 - Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction com...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  62     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1988 Nov 
Date Detail:
Created Date:  1988-12-02     Completed Date:  1988-12-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1000-4     Citation Subset:  AIM; IM    
Department of Internal Medicine, Harper Hospital/Detroit Medical Center, Michigan 48201.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Cardiomegaly / mortality*
Clinical Trials as Topic
Creatine Kinase / blood
Diltiazem / therapeutic use
Myocardial Infarction / drug therapy,  mortality*
Random Allocation
Regression Analysis
Retrospective Studies
Risk Factors
Reg. No./Substance:
0/Isoenzymes; 42399-41-7/Diltiazem; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased circulating atrial natriuretic factor (ANF) release during induced ventricular tachycardia...
Next Document:  Location of an acute myocardial infarct in patients with a healed myocardial infarct: analysis of 12...